Target and Its Patented Drug(s)
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T56510 | Target Info | |||
Target Name | Apoptosis regulator Bcl-xL (BCL-xL) | ||||
Synonyms | Bcl2like protein 1; Bcl2L1; Bcl2-L-1; Bcl-XL; Bcl-2-like protein 1; BCLX; BCL2L; Apoptosis regulator Bcl-X | ||||
Target Type | Clinical trial Target | ||||
Gene Name | BCL2L1 | ||||
Biochemical Class | B-cell lymphoma Bcl-2 | ||||
UniProt ID |
Patent(s) and the Corresponding Patented Drug(s) | Top | ||||
---|---|---|---|---|---|
World Intellectual Property Organization (WIPO) | |||||
Patent ID | WO2010024783 | ||||
Title | Biarylrhodanine and Pyridylrhodanine Compounds and Their Use. | ||||
Abstract | The present invention pertains generally to the field of therapeutic compounds, and more specifically to compounds related to rhodanine, which compounds are inter alia inhibitors and/or binders of antiapoptotic/pro-survival Bcl-2 proteins such as Bcl-XL and/or Mcl-1. More specifically, the present invention is concerned with Rhodanine- based Pan-Bcl-2 inhibitors and Mcl-1 -specific inhibitors as anti-cancer compounds. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit and/or bind Bcl-2 proteins such as Bcl-XL and/or Mcl-1, and in the treatment of diseases and conditions that are mediated by Bcl-2 proteins, that are ameliorated by the inhibition of Bcl-2 protein function (such as Bcl-XL and/or Mcl-1 ) including proliferative conditions such as cancer, optionally in combination with another agent. | ||||
Applicant(s) | Agency for Science, Technology and Research | ||||
Representative Drug(s) | D0F9QC | Drug Info | Ki > 100000 nM | Click to Show More | [1] |
2 | D09XWR | Drug Info | Ki > 150000 nM | [1] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.